Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients.

Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G.

Lung Cancer. 2014 Dec;86(3):324-8. doi: 10.1016/j.lungcan.2014.10.002. Epub 2014 Oct 12.

PMID:
25453846
[PubMed - in process]
2.

Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial.

Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua R, Crino L, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Riccardi F, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Clin Lung Cancer. 2015 Jan;16(1):67-70. doi: 10.1016/j.cllc.2014.09.001. Epub 2014 Sep 28.

PMID:
25450879
[PubMed - in process]
3.

First-Line Chemotherapy Treatment of Advanced Non-Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?

Tiseo M, Ardizzoni A, Boni L.

J Thorac Oncol. 2014 Nov;9(11):e82. doi: 10.1097/JTO.0000000000000272. No abstract available.

PMID:
25436810
[PubMed - in process]
4.

MET and Small-Cell Lung Cancer.

Gelsomino F, Rossi G, Tiseo M.

Cancers (Basel). 2014 Oct 13;6(4):2100-15. doi: 10.3390/cancers6042100. Review.

PMID:
25314153
[PubMed]
Free Article
5.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

PMID:
25242668
[PubMed - in process]
6.

CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?

De Filippo M, Saba L, Silva M, Zagaria R, Concari G, Nizzoli R, Bozzetti C, Tiseo M, Ardizzoni A, Lipia S, Paladini I, Macarini L, Carrafiello G, Brunese L, Rotondo A, Rossi C.

Diagn Interv Radiol. 2014 Sep-Oct;20(5):421-5. doi: 10.5152/dir.2014.14019.

PMID:
25163758
[PubMed - in process]
Free Article
7.

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.

Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A.

Lung Cancer. 2014 Oct;86(1):91-5. doi: 10.1016/j.lungcan.2014.07.022. Epub 2014 Aug 2.

PMID:
25130081
[PubMed - in process]
8.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
[PubMed - in process]
9.

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A.

Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. No abstract available.

PMID:
24988929
[PubMed - indexed for MEDLINE]
10.

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

Ardizzoni A, Tiseo M, Boni L.

Eur J Cancer. 2014 Sep;50(13):2211-8. doi: 10.1016/j.ejca.2014.06.002. Epub 2014 Jun 26.

PMID:
24981975
[PubMed - indexed for MEDLINE]
11.

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.

Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A.

Anticancer Res. 2014 Jun;34(6):3185-8.

PMID:
24922692
[PubMed - indexed for MEDLINE]
12.

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.

Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.

PMID:
24898067
[PubMed - in process]
Free PMC Article
13.

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.

Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A.

Tumori. 2014 Jan-Feb;100(1):e20-3. doi: 10.1700/1430.15832.

PMID:
24675505
[PubMed - indexed for MEDLINE]
14.

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M, Bortesi B, Goldoni M, Silini EM, De Palma G, Mutti A, Ardizzoni A.

Lung Cancer. 2014 Feb;83(2):265-71. doi: 10.1016/j.lungcan.2013.12.001. Epub 2013 Dec 12.

PMID:
24388705
[PubMed - indexed for MEDLINE]
15.

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, Fantini R, Rossi G.

Tumori. 2013 Sep-Oct;99(5):e229-32. doi: 10.1700/1377.15321.

PMID:
24362875
[PubMed - indexed for MEDLINE]
16.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
[PubMed - indexed for MEDLINE]
17.

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G.

Endocr Relat Cancer. 2013 Dec 16;21(1):1-16. doi: 10.1530/ERC-13-0246. Print 2014 Feb.

PMID:
24344249
[PubMed - indexed for MEDLINE]
18.

YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.

Corradi M, Goldoni M, Alinovi R, Tiseo M, Ampollini L, Bonini S, Carbognani P, Casalini A, Mutti A.

Anticancer Res. 2013 Dec;33(12):5517-24.

PMID:
24324091
[PubMed - indexed for MEDLINE]
19.

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.

Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, Ruffini L, Bartolotti M, Bortesi B, Fumarola C, Caffarra C, Cavazzoni A, Alfieri RR, Petronini PG, Bordonaro R, Bruzzi P, Ardizzoni A, Soto Parra HJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):299-307. doi: 10.1007/s00280-013-2356-x. Epub 2013 Nov 21.

PMID:
24258456
[PubMed - indexed for MEDLINE]
20.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR.

PLoS One. 2013 Oct 22;8(10):e78656. doi: 10.1371/journal.pone.0078656. eCollection 2013.

PMID:
24167634
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk